Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March

Apollomics Inc. (NASDAQ:APLM) was the target of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 8,621 shares, a decline of 30.9% from the February 26th total of 12,471 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 7,156 shares, the days-to-cover ratio is currently 1.2 days.

Apollomics Trading Up 0.1%

NASDAQ APLM opened at $17.65 on Friday. The company has a 50 day moving average of $19.51 and a 200-day moving average of $18.52. Apollomics has a 1-year low of $3.66 and a 1-year high of $42.12.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new position in shares of Apollomics Inc. (NASDAQ:APLM) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics at the end of the most recent quarter. Institutional investors and hedge funds own 19.13% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Wall Street Zen raised Apollomics from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Apollomics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.